Epeius Biotechnologies Corporation announced more stunning results of its pioneering clinical studies of Rexin-G, the world’s first and, so far only, tumor-targeted genetic medicine to be validated in the clinic.
By medicalnewstoday.com
Leave a Reply
You must be logged in to post a comment.
- EXCLUSIVE: Sen. Olympia Snowe Explains Her Lone ‘Yes’ to Health Care Bill
- ‘Mentally-ill’ Briton faces execution in China
- Iraq approves return of small British force
- Boyzone member death cause revealed
- Clinton: Russia yet to back Iran sanctions
- ‘Herminator’ Maier calls time on skiing career
- U.S. official: Turkey’s delay of exercise political
- Arrests of 10 linked to Basque separatists
- Bomber: I regret trying to kill Thatcher
- Unable to scream because her throat had been slit